UPF-648 is a kynurenine 3-monooxygenase (KMO) inhibitor. KMO is a key enzyme that is part of the kynurenine pathway, which is a metabolic pathway that utilizes tryptophan to produce nicotinamide adenine dinucleotide (NAD+). KMO is a potential therapeutic target for treating neurodegenerative and psychiatric disorders.
